Free tool
FAERS Monitor: Lotemax
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020583 or its brand name (Lotemax, Loteprednol Etabonate). Reports on generic versions are filed under their own applications.
Reports
4,307
Serious
1,582
37% of reports
Hospitalization
543
Death reported
124
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye pain600
- eye irritation483
- off label use353
- drug ineffective329
- vision blurred312
- ocular hyperaemia279
- headache230
- fatigue216
- dry eye180
- pain169
- nausea168
- eye swelling153
- lacrimation increased149
- visual impairment145
- condition aggravated140
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 15 |
| 2006 | 22 |
| 2007 | 16 |
| 2008 | 33 |
| 2009 | 65 |
| 2010 | 107 |
| 2011 | 77 |
| 2012 | 137 |
| 2013 | 88 |
| 2014 | 152 |
| 2015 | 275 |
| 2016 | 388 |
| 2017 | 341 |
| 2018 | 318 |
| 2019 | 350 |
| 2020 | 277 |
| 2021 | 255 |
| 2022 | 291 |
| 2023 | 286 |
| 2024 | 305 |
| 2025 | 300 |
| 2026 | 201 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,852 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eye painSignal | 600 | 52.5 | 48.7 | 30,007 |
| eye irritationSignal | 483 | 41.3 | 38.0 | 18,854 |
| ocular hyperaemiaSignal | 279 | 28.9 | 25.8 | 7,452 |
| lacrimation increasedSignal | 149 | 24.2 | 20.7 | 3,279 |
| eye swellingSignal | 153 | 20.2 | 17.3 | 2,761 |
| dry eyeSignal | 180 | 17.7 | 15.3 | 2,811 |
| vision blurredSignal | 312 | 11.1 | 10.0 | 2,875 |
| visual impairmentSignal | 145 | 5.7 | 4.9 | 563 |
| condition aggravatedSignal | 140 | 2.2 | 1.9 | 97 |
| off label use | 353 | 2.0 | 1.8 | 175 |
| headache | 230 | 1.8 | 1.6 | 82 |
| fatigue | 216 | 1.4 | 1.2 | 20 |
| pain | 169 | 1.3 | 1.2 | 15 |
| drug ineffective | 329 | 1.2 | 1.1 | 14 |
| nausea | 168 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.